Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients

Dennis J. Cotter, Kevin Stefanik, Yi Zhang, Mae Thamer, Daniel O Scharfstein, James Kaufman

Research output: Contribution to journalArticle

Abstract

To evaluate the use of hematocrit as a surrogate end point for survival among end-stage renal disease (ESRD) patients treated with epoetin. Using United States Renal Data System (USRDS) data, we conducted an observational prospective study to analyze the relationships among epoetin dose, hematocrit, and survival for 31,301 facility-based hemodialysis patients incident to ESRD therapy in 1998. To address our objective, we used criteria developed by Prentice based on results from a Cox regression model. Results indicate that hematocrit is inversely associated with epoetin dose. For the same epoetin treatment-related achieved hematocrit levels, there were widely varying treatment-related survival outcomes, thereby challenging a central criterion required to empirically validate a surrogate end point. Our results support earlier clinical trial and epidemiological data suggesting that hematocrit may not be a valid surrogate for survival among the epoetin-treated renal failure population. We hypothesize that hematocrit may not be in the causal pathway or that epoetin may have important mechanisms of action apart from increasing hematocrit. Effective treatment for anemia may therefore not be simply a matter of increasing hematocrit. This study has potential implications for revising the existing treatment guidelines for anemia management and selecting an appropriate treatment regimen.

Original languageEnglish (US)
Pages (from-to)1086-1095
Number of pages10
JournalJournal of Clinical Epidemiology
Volume57
Issue number10
DOIs
StatePublished - Oct 2004

Fingerprint

Hematocrit
Renal Dialysis
Biomarkers
Survival
Chronic Kidney Failure
Anemia
Therapeutics
Proportional Hazards Models
Information Systems
Observational Studies
Renal Insufficiency
Clinical Trials
Prospective Studies
Guidelines
Kidney
Population

Keywords

  • Anemia, management of
  • Causal effect
  • End point, surrogate
  • Epoetin
  • Hematocrit, target
  • Outcome assessment
  • Survival

ASJC Scopus subject areas

  • Medicine(all)
  • Public Health, Environmental and Occupational Health
  • Epidemiology

Cite this

Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. / Cotter, Dennis J.; Stefanik, Kevin; Zhang, Yi; Thamer, Mae; Scharfstein, Daniel O; Kaufman, James.

In: Journal of Clinical Epidemiology, Vol. 57, No. 10, 10.2004, p. 1086-1095.

Research output: Contribution to journalArticle

Cotter, Dennis J. ; Stefanik, Kevin ; Zhang, Yi ; Thamer, Mae ; Scharfstein, Daniel O ; Kaufman, James. / Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. In: Journal of Clinical Epidemiology. 2004 ; Vol. 57, No. 10. pp. 1086-1095.
@article{9fc5c75a437d4d218bb4d85b34aec882,
title = "Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients",
abstract = "To evaluate the use of hematocrit as a surrogate end point for survival among end-stage renal disease (ESRD) patients treated with epoetin. Using United States Renal Data System (USRDS) data, we conducted an observational prospective study to analyze the relationships among epoetin dose, hematocrit, and survival for 31,301 facility-based hemodialysis patients incident to ESRD therapy in 1998. To address our objective, we used criteria developed by Prentice based on results from a Cox regression model. Results indicate that hematocrit is inversely associated with epoetin dose. For the same epoetin treatment-related achieved hematocrit levels, there were widely varying treatment-related survival outcomes, thereby challenging a central criterion required to empirically validate a surrogate end point. Our results support earlier clinical trial and epidemiological data suggesting that hematocrit may not be a valid surrogate for survival among the epoetin-treated renal failure population. We hypothesize that hematocrit may not be in the causal pathway or that epoetin may have important mechanisms of action apart from increasing hematocrit. Effective treatment for anemia may therefore not be simply a matter of increasing hematocrit. This study has potential implications for revising the existing treatment guidelines for anemia management and selecting an appropriate treatment regimen.",
keywords = "Anemia, management of, Causal effect, End point, surrogate, Epoetin, Hematocrit, target, Outcome assessment, Survival",
author = "Cotter, {Dennis J.} and Kevin Stefanik and Yi Zhang and Mae Thamer and Scharfstein, {Daniel O} and James Kaufman",
year = "2004",
month = "10",
doi = "10.1016/j.jclinepi.2004.05.002",
language = "English (US)",
volume = "57",
pages = "1086--1095",
journal = "Journal of Clinical Epidemiology",
issn = "0895-4356",
publisher = "Elsevier USA",
number = "10",

}

TY - JOUR

T1 - Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients

AU - Cotter, Dennis J.

AU - Stefanik, Kevin

AU - Zhang, Yi

AU - Thamer, Mae

AU - Scharfstein, Daniel O

AU - Kaufman, James

PY - 2004/10

Y1 - 2004/10

N2 - To evaluate the use of hematocrit as a surrogate end point for survival among end-stage renal disease (ESRD) patients treated with epoetin. Using United States Renal Data System (USRDS) data, we conducted an observational prospective study to analyze the relationships among epoetin dose, hematocrit, and survival for 31,301 facility-based hemodialysis patients incident to ESRD therapy in 1998. To address our objective, we used criteria developed by Prentice based on results from a Cox regression model. Results indicate that hematocrit is inversely associated with epoetin dose. For the same epoetin treatment-related achieved hematocrit levels, there were widely varying treatment-related survival outcomes, thereby challenging a central criterion required to empirically validate a surrogate end point. Our results support earlier clinical trial and epidemiological data suggesting that hematocrit may not be a valid surrogate for survival among the epoetin-treated renal failure population. We hypothesize that hematocrit may not be in the causal pathway or that epoetin may have important mechanisms of action apart from increasing hematocrit. Effective treatment for anemia may therefore not be simply a matter of increasing hematocrit. This study has potential implications for revising the existing treatment guidelines for anemia management and selecting an appropriate treatment regimen.

AB - To evaluate the use of hematocrit as a surrogate end point for survival among end-stage renal disease (ESRD) patients treated with epoetin. Using United States Renal Data System (USRDS) data, we conducted an observational prospective study to analyze the relationships among epoetin dose, hematocrit, and survival for 31,301 facility-based hemodialysis patients incident to ESRD therapy in 1998. To address our objective, we used criteria developed by Prentice based on results from a Cox regression model. Results indicate that hematocrit is inversely associated with epoetin dose. For the same epoetin treatment-related achieved hematocrit levels, there were widely varying treatment-related survival outcomes, thereby challenging a central criterion required to empirically validate a surrogate end point. Our results support earlier clinical trial and epidemiological data suggesting that hematocrit may not be a valid surrogate for survival among the epoetin-treated renal failure population. We hypothesize that hematocrit may not be in the causal pathway or that epoetin may have important mechanisms of action apart from increasing hematocrit. Effective treatment for anemia may therefore not be simply a matter of increasing hematocrit. This study has potential implications for revising the existing treatment guidelines for anemia management and selecting an appropriate treatment regimen.

KW - Anemia, management of

KW - Causal effect

KW - End point, surrogate

KW - Epoetin

KW - Hematocrit, target

KW - Outcome assessment

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=7444268479&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7444268479&partnerID=8YFLogxK

U2 - 10.1016/j.jclinepi.2004.05.002

DO - 10.1016/j.jclinepi.2004.05.002

M3 - Article

C2 - 15528060

AN - SCOPUS:7444268479

VL - 57

SP - 1086

EP - 1095

JO - Journal of Clinical Epidemiology

JF - Journal of Clinical Epidemiology

SN - 0895-4356

IS - 10

ER -